{"id":"NCT00447499","sponsor":"Ipsen","briefTitle":"Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel","officialTitle":"A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2007-03-14","resultsPosted":"2010-12-20","lastUpdate":"2020-11-20"},"enrollment":59,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acromegaly"],"interventions":[{"type":"DRUG","name":"Somatuline Autogel (lanreotide acetate)","otherNames":[]},{"type":"BEHAVIORAL","name":"Home administration","otherNames":[]}],"arms":[{"label":"Somatuline Autogel (lanreotide acetate)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.","primaryOutcome":{"measure":"The Percentage of Subjects or Their Partners That Are Competent to Self-administer Somatuline Autogel at the End of the Study, (Week 24/Early Termination), as Assessed by the Competence Questionnaire Score.","timeFrame":"24 weeks","effectByArm":[{"arm":"Somatuline Autogel (Lanreotide Acetate) Injection","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":13},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["19898989"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":59},"commonTop":["Diarrhoea","Headache","Injection Site Pain","Nausea","Abdominal Pain"]}}